Dose-related effects of nebulized metaproterenol in asthmatic children

Ellen F. Crain, Jeffrey C. Gershel, Avrom Kadar, Theodore A. Kastner

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The dose-related effects of inhaled 5% metaproterenol solution in asthmatic children between the ages of six and 12 years with acute bronchospasm were evaluated. Tests included FEV<inf>1.0</inf>, FEF<inf>25–75</inf>, and PEFR. For entry into the study, subjects were required to have an FEV<inf>1.0</inf> or an FEF<inf>25–75</inf> less than 80% of the child’s predicted normal value based on height and race. Sixty children were randomly assigned in double-blind fashion to receive one of four different doses of 5% metaproterenol inhalant solution: 0.0 ml (placebo), 0.1 ml, 0.2 ml, or 0.3 ml. Drug efficacy was assessed by spirometry using a DeVilbiss Surveyor I spirometer. Spirometry was performed prior to inhalation of the test dose (baseline) and four times after inhalation: Immediately after and 15, 30, and 60 minutes after inhalation. Patients in the three treated groups had significantly higher peak post-dose FEV<inf>1.0</inf> and FEF<inf>25–75</inf> than the placebo group but were not significantly different from one another. There was a significant relationship between dose and incidence of side effects. These results suggest that 0.1 ml (5 mg) of nebulized metaproterenol may provide as much bronchodilatation as higher doses with fewer side effects.

Original languageEnglish (US)
Pages (from-to)143-146
Number of pages4
JournalPediatric Emergency Care
Volume3
Issue number3
StatePublished - 1987

Fingerprint

Metaproterenol
Inhalation
Spirometry
Placebos
Peak Expiratory Flow Rate
Bronchial Spasm
Reference Values
Incidence
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Emergency Medicine
  • Pediatrics, Perinatology, and Child Health
  • Nursing(all)

Cite this

Dose-related effects of nebulized metaproterenol in asthmatic children. / Crain, Ellen F.; Gershel, Jeffrey C.; Kadar, Avrom; Kastner, Theodore A.

In: Pediatric Emergency Care, Vol. 3, No. 3, 1987, p. 143-146.

Research output: Contribution to journalArticle

Crain, EF, Gershel, JC, Kadar, A & Kastner, TA 1987, 'Dose-related effects of nebulized metaproterenol in asthmatic children', Pediatric Emergency Care, vol. 3, no. 3, pp. 143-146.
Crain, Ellen F. ; Gershel, Jeffrey C. ; Kadar, Avrom ; Kastner, Theodore A. / Dose-related effects of nebulized metaproterenol in asthmatic children. In: Pediatric Emergency Care. 1987 ; Vol. 3, No. 3. pp. 143-146.
@article{f1fdab1e8c9f4a37931d01b09aa70999,
title = "Dose-related effects of nebulized metaproterenol in asthmatic children",
abstract = "The dose-related effects of inhaled 5{\%} metaproterenol solution in asthmatic children between the ages of six and 12 years with acute bronchospasm were evaluated. Tests included FEV1.0, FEF25–75, and PEFR. For entry into the study, subjects were required to have an FEV1.0 or an FEF25–75 less than 80{\%} of the child’s predicted normal value based on height and race. Sixty children were randomly assigned in double-blind fashion to receive one of four different doses of 5{\%} metaproterenol inhalant solution: 0.0 ml (placebo), 0.1 ml, 0.2 ml, or 0.3 ml. Drug efficacy was assessed by spirometry using a DeVilbiss Surveyor I spirometer. Spirometry was performed prior to inhalation of the test dose (baseline) and four times after inhalation: Immediately after and 15, 30, and 60 minutes after inhalation. Patients in the three treated groups had significantly higher peak post-dose FEV1.0 and FEF25–75 than the placebo group but were not significantly different from one another. There was a significant relationship between dose and incidence of side effects. These results suggest that 0.1 ml (5 mg) of nebulized metaproterenol may provide as much bronchodilatation as higher doses with fewer side effects.",
author = "Crain, {Ellen F.} and Gershel, {Jeffrey C.} and Avrom Kadar and Kastner, {Theodore A.}",
year = "1987",
language = "English (US)",
volume = "3",
pages = "143--146",
journal = "Pediatric Emergency Care",
issn = "0749-5161",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Dose-related effects of nebulized metaproterenol in asthmatic children

AU - Crain, Ellen F.

AU - Gershel, Jeffrey C.

AU - Kadar, Avrom

AU - Kastner, Theodore A.

PY - 1987

Y1 - 1987

N2 - The dose-related effects of inhaled 5% metaproterenol solution in asthmatic children between the ages of six and 12 years with acute bronchospasm were evaluated. Tests included FEV1.0, FEF25–75, and PEFR. For entry into the study, subjects were required to have an FEV1.0 or an FEF25–75 less than 80% of the child’s predicted normal value based on height and race. Sixty children were randomly assigned in double-blind fashion to receive one of four different doses of 5% metaproterenol inhalant solution: 0.0 ml (placebo), 0.1 ml, 0.2 ml, or 0.3 ml. Drug efficacy was assessed by spirometry using a DeVilbiss Surveyor I spirometer. Spirometry was performed prior to inhalation of the test dose (baseline) and four times after inhalation: Immediately after and 15, 30, and 60 minutes after inhalation. Patients in the three treated groups had significantly higher peak post-dose FEV1.0 and FEF25–75 than the placebo group but were not significantly different from one another. There was a significant relationship between dose and incidence of side effects. These results suggest that 0.1 ml (5 mg) of nebulized metaproterenol may provide as much bronchodilatation as higher doses with fewer side effects.

AB - The dose-related effects of inhaled 5% metaproterenol solution in asthmatic children between the ages of six and 12 years with acute bronchospasm were evaluated. Tests included FEV1.0, FEF25–75, and PEFR. For entry into the study, subjects were required to have an FEV1.0 or an FEF25–75 less than 80% of the child’s predicted normal value based on height and race. Sixty children were randomly assigned in double-blind fashion to receive one of four different doses of 5% metaproterenol inhalant solution: 0.0 ml (placebo), 0.1 ml, 0.2 ml, or 0.3 ml. Drug efficacy was assessed by spirometry using a DeVilbiss Surveyor I spirometer. Spirometry was performed prior to inhalation of the test dose (baseline) and four times after inhalation: Immediately after and 15, 30, and 60 minutes after inhalation. Patients in the three treated groups had significantly higher peak post-dose FEV1.0 and FEF25–75 than the placebo group but were not significantly different from one another. There was a significant relationship between dose and incidence of side effects. These results suggest that 0.1 ml (5 mg) of nebulized metaproterenol may provide as much bronchodilatation as higher doses with fewer side effects.

UR - http://www.scopus.com/inward/record.url?scp=0023607961&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023607961&partnerID=8YFLogxK

M3 - Article

VL - 3

SP - 143

EP - 146

JO - Pediatric Emergency Care

JF - Pediatric Emergency Care

SN - 0749-5161

IS - 3

ER -